TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.


Nkarta, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer, or NK, cell therapies to treat cancer. The Company’s approach for cellular immunotherapy involves chimeric antigen receptors, or CARs, on the surface of an NK cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. The Company’s two co-lead product candidates are NKX101 and NKX019. NKX101 is designed to leverage the power of innate NK biology to detect and kill cancerous cells. NKX019 is based on the ability to treat a variety of B cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells. Beyond these two lead products, the Company is engaged in preclinical discovery for another CAR-NK product candidate.